Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sinovac Omicron booster in adults in Hong Kong
NCT05411471Phase 2Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Omicron Inactivated COVID-19 Vaccine (Vero Cell) in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Geometric Mean Titre of Neutralization Antibody at Day 14 and Adverse Events at 28 days. Started Jun 2022; status: completed.
02
Drugs
Omicron Inactivated COVID-19 Vaccine (Vero Cell)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05411471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411471.